



## **Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results Selected for an Oral Presentation at the 2022 AACR Annual Meeting**

March 8, 2022

- *Four Additional Abstracts Selected as Poster Presentations at the Meeting*

- *Company to Host Conference Call on Monday, April 11, 2022 at 8:30 a.m. ET*

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Mar. 8, 2022-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (*Bicycle®*) technology, today announced that interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4, has been selected for an oral presentation at the upcoming 2022 American Association for Cancer Research Annual Meeting, being held April 8-13, 2022 in New Orleans, LA. The Company will host a conference call to discuss the data from the presentation on Monday, April 11, 2022 at 8:30 a.m. ET.

### **Oral Presentation Details**

**Title:** BT8009-100 Phase I/II Study of Novel Bi-Cyclic Peptide and MMAE Conjugate BT8009 in Patients with Advanced Malignancies Associated with Nectin-4 Expression

**Abstract #:** 7971

**Presenter:** Meredith McKean, Sarah Cannon Research Institute at Tennessee Oncology

**Session Title:** Biomarker Advances in Clinical Trials

**Date/Time:** Sunday, April 10, 2022 at 4:00 p.m. ET

### **Poster Presentation Details**

**Title:** Development of a CD137 Receptor Occupancy Assay to Support the Phase I/II Study of BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA™)

**Abstract #:** 5555

**Presenter:** Heather Cohen, Bicycle Therapeutics

**Session Title:** Immune Response to Therapies / Immune Monitoring and Clinical Correlates

**Date/Time:** Monday, April 11, 2022 at 2:30 p.m. ET

**Title:** Activity of the Erythropoietin-Producing Hepatocellular A2 Receptor (EphA2) Targeting Bicycle® Toxin Conjugate (BTC™) BCY6033 in EGFR Inhibitor Resistant Non-Small Lung Cancer (NSCLC) Patient Derived Xenografts

**Abstract #:** 333

**Presenter:** Kenneth Ngo, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute

**Session Title:** Biological Therapeutic Agents and Novel Drugs

**Date/Time:** Sunday, April 10, 2022 at 2:30 p.m. ET

**Title:** Modeling the cDC1 Ex Vivo and In Vitro: Development and Characterization of a Conventional Dendritic Cell Culture System to Support Drug Discovery

**Abstract #:** 4230

**Presenter:** Laura Goodfield, Bicycle Therapeutics

**Session Title:** Immunomodulatory Agents and Interventions 3

**Date/Time:** Wednesday, April 13, 2022 at 10:00 a.m. ET

**Title:** Generation of a Bicycle NK-TICA™, a Novel NK Cell Engaging Molecule Designed to Induce Targeted Tumor Cytotoxicity

**Abstract #:** 4233

**Presenter:** Fay Dufort, Bicycle Therapeutics

**Session Title:** Immunomodulatory Agents and Interventions

**Date/Time:** Wednesday, April 13, 2022 at 10:00 a.m. ET

The posters and a copy of the presentation will be available on the Publications section of [bicycletherapeutics.com](https://bicycletherapeutics.com) following presentation.

### **Conference Call Details**

Bicycle Therapeutics will host a conference call and webcast on Monday, April 11, 2022 at 8:30 a.m. ET to review the data being presented. To access the call, please dial (800) 377-9118 (domestic) or (409) 937-8920 (international) and provide the Conference ID 2775710. A live webcast of the presentation will be available on the Investors & Media section of the Bicycle website, [bicycletherapeutics.com](https://bicycletherapeutics.com).

### **About Bicycle Therapeutics**

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as *Bicycles*, for diseases that are underserved by existing therapeutics. *Bicycles* are fully synthetic short peptides constrained with small molecule scaffolds to form

two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making *Bicycles* attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation *Bicycle* Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a *Bicycle* TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA. For more information, visit [bicycletherapeutics.com](https://bicycletherapeutics.com).

### Forward Looking Statements

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding Bicycle’s anticipated advancement of its product candidates, including BT5528, BT8009, BT7480 and BT1718, and participation in the AACR Annual Meeting. Bicycle may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the intentions disclosed in these forward-looking statements as a result of various factors, including: Bicycle’s abilities to meet other anticipated deadlines presented by the ongoing COVID-19 pandemic; uncertainties inherent in the initiation and completion of clinical trials and clinical development of Bicycle’s product candidates; ; and other important factors, any of which could cause Bicycle’s actual results to differ from those contained in the forward-looking statements, and which are described in greater detail in the section entitled “Risk Factors” in Bicycle’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 1, 2022, as well as in other filings Bicycle may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and Bicycle expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220308005201/en/): <https://www.businesswire.com/news/home/20220308005201/en/>

### Investors:

David Borah, CFA  
VP, Capital Markets & Investor Relations  
[david.borah@bicycletx.com](mailto:david.borah@bicycletx.com)  
617-203-8300

### Media:

Consilium Strategic Communications  
Sukaina Virji or Mary-Jane Elliott  
[bicycle@consilium-comms.com](mailto:bicycle@consilium-comms.com)

Source: Bicycle Therapeutics plc